Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjects

Clinical and Diagnostic Laboratory Immunology

Volumn 8, Issue 4, 2001, Pages 671-677

  De Paoli, P ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; INTERLEUKIN 2;

APOPTOSIS; AUTOIMMUNITY; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE;

APOPTOSIS; AUTOIMMUNITY; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CHEMOKINES; CYTOKINES; HIV ANTIGENS; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOID TISSUE; RECEPTORS, CHEMOKINE; THYMUS GLAND;

EID: 0034973302     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.8.4.671-677.2001     Document Type: Short Survey

References (70)

1. IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection
2. Programmed cell death and AIDS: From hypothesis to experiment
3. Efficacy of low-dose sc IL-2 to treat advanced HIV-1 in persons with ≤250/μl CD4 T cells and undetectable plasma virus load
4. Hypothyroidism after treatment with IL-2 and LAK cells
5. Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy
6. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes
7. Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection
8. Differential responses of T cell subsets: Possible role in the immunopathogenesis of AIDS
9. + lymphocyte apoptosis in HIV+ patients
10. Th1-Th2 hypothesis in HIV infection: New insights
11. Th1/Th2 cytokine modulation of T-cell programmed cell death as a model for HIV pathogenesis
12. Host factors in the pathogenesis of HIV disease
13. Subcutaneous administration of IL-2 in HIV type 1-infected persons
14. Immunologic and virologic effects of sc IL-2 in combination with antiretroviral therapy
15. Effects of sc IL-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ patients
16. Kinetics of lympholkine production in patients treated with HAART and IL-2
17. Changes in thymic function with age and during the treatment of HIV infection
18. Chemokines and HIV second receptors
19. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
20. Cytokines, plasma activation markers and clinically relevant surrogate markers in HIV infection
21. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer
22. Reduction of the HIV-1 infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs
23. Immune reconstitution in HIV infection
24. Population biology of HIV-1 infection: Viral and CD4 T cell demographics and dynamics in lymphatic tissue
25. Effect of recent thymic emigrant on progression of HIV-1 disease
26. Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection
27. T cell division in HIV-1 infection is mainly due to immune activation: A longitudinal analysis in patients before and during HAART
28. Increased cell division, but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection
29. Antiretroviral therapy reverses HIV-associated abnormalities in lymphocyte apoptosis
30. Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens
31. Increases in CD4 T lymphocytes with intermittent courses of IL-2 in patients with HIV infection
32. The role of nasopharyngeal lymphoid tissue
33. IL-2 inhibits HIV-1 replication in human macrophages by modulating expression of CD4 and CCR-5
34. Use of IL-2 in patients with AIDS
35. + T cells
36. Comparison of sc and iv IL-2 in asymptomatic HIV-1 infection: A randomised controlled trial
37. Long-lasting recovery in T cell function and viral load reduction after HAART in advanced HIV disease
38. Clinical effects and toxicity of IL-2 in patients with cancer
39. Identification of functional subsets by flow cytometry: Intracellular detection of cytokine expression
40. High prevalence of thymic tissue in adults with HIV-1 infection
41. The antitumor efficacy of LAK cells and recombinant IL-2 in vivo
42. + T lymphocyte subpopulations
43. Decay kinetics of HIV-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
44. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
45. Lymphocyte response and cytokines
46. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry
47. Pharmacokinetic studies with recombinant cytokines: Scientific issues and practical considerations
48. Pharmacokinetic modeling of recombinant IL-2 in patients with HIV infection
49. Functional T cell reconstitution in human immunodeficiency type 1-specific cell-mediated immunity during highly active antiretroviral therapy
50. Direct evidence for thymic function in adult humans
51. - T cells in acute HIV infection in vitro
52. An alternative view of the Th1/Th2 switch hypothesis in HIV infection
53. Vigorous HIV-1 specific CD4 T cell responses associated with control of viremia
54. A progress report on treatment of 157 patients with advanced cancer using LAK cells and IL-2 or high-dose IL-2
55. A randomized, controlled 24-week study of intermittent sc IL-2 in HIV-1 infected patients in Thailand
56. Apoptosis of CD4 and CD19 cells during HIV-1 infection. Correlation with clinical progression, viral load and loss of humoral immunity
57. Safety and effects of IL-2 plus AZT in asymptomatic individuals infected with HIV
58. Concomitant therapy with sc IL-2 and AZT plus ddI in patients with early stage HIV infection
59. Rational interleukin-2 therapy
60. Interleukin-2
61. Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during HAART for HIV-1 infection
62. Production of β-chemokines in HIV infection: Evidence that high levels of MIP-1 beta are associated with a decreased risk of HIV disease progression
63. Immunomodulatory properties and toxicity of IL-2 in patients with cancer
64. Quantitation of immunosuppression by flow cytometric measurement of the capacity of T cells for IL-2 production
65. Therapy of AIDS with recombinant IL-2
66. Abnormal intracellular IL-2 and IFN-γ production as HIV-1 associated markers of immune dysfunction
67. Loss of inducible virus in CD45RA naive cells after HIV-1 entry accounts for preferential viral replication in CD45R0 memory cells
68. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with HAART or HAART + IL-2
69. Measuring TRE in blood of normal and HIV-1 infected individuals before and after effective therapy
70. Acute activation of CD8 T lymphocytes in IL-2 treated HIV-infected patients